ReviewCurrent opinion in pulmonary medicine2022
The role of PET in the management of sarcoidosis.
Review in Current opinion in pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Meta-analysis of [European radiology · 2025Pooled it
- Article
- Spatiotemporal Heterogeneity in Isolated Neurosarcoidosis: Diagnostic Insights from Multimodal Imaging.Neurology and therapy · 2026Article
- Uncovering Sex and Gender Differences in Sarcoidosis: A Systematic Review of Current Evidence.Journal of personalized medicine · 2026Review
- Pulmonary hypertension associated with sarcoidosis: current and future treatment landscape.Future cardiology · 2025Article
- The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis.Current rheumatology reports · 2025Review
- Cardiac sarcoidosis recurrence post-heart transplant: A critical literature and case report.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Chronic Sarcoidosis: Diagnostic Difficulties and Search for New Criteria of Inflammatory Activity (A Case Report and Literature Review).Journal of clinical medicine · 2024Review
- Article
- Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions.Cureus · 2024Review
- High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities.Diagnostics (Basel, Switzerland) · 2024Review
- Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis.Journal of clinical medicine · 2023Review
- Sarcoidosis-Related Uveitis: A Review.Journal of clinical medicine · 2023Review
- Decoding sarcoidosis chronicity through phenotypic profiling.Therapeutic advances in respiratory diseaseArticle
- Advancements in Dermatological Imaging Modalities.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPET has emerged as method to determine the location and extent of disease activity in sarcoidosis. As most clinicians do not routinely utilize PET in the management of sarcoidosis, an understanding of the imaging technique is needed to comprehend the impact that PET abnormalities have on diagnosis, prognosis, and treatment. RECENT
findingsAlthough PET can detect inflammation because of sarcoidosis throughout the body, it is most often utilized for the diagnosis of cardiac sarcoidosis for which it may provide information about prognosis and adverse events. Whenever PET is combined with cardiac magnetic resonance (CMR), clinicians may be able to increase the diagnostic yield of imaging. Furthermore, PET abnormalities have the potential to be utilized in the reduction or augmentation of therapy based on an individual's response to treatment. Although various biomarkers are used to monitor disease activity in sarcoidosis, an established and reproducible relationship between PET and biomarkers does not exist. SUMMARY: PET has the potential to improve the diagnosis of sarcoidosis and alter treatment decisions but prospective trials are needed to define the role of PET while also standardizing the performance and interpretation of the imaging modality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.